AQR Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

AQR Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.25M	Buy	161,278 +117,875	+272%	+$860K	﹤0.01%	2646
2025 Q4	$266K	Buy	+43,403	New	+$469K	﹤0.01%	3224
2025 Q3	–	Sell	-11,218	Closed	-$146K	–	3466
2025 Q2	$146K	Sell	11,218 -849	-7%	-$10K	﹤0.01%	3115
2025 Q1	$128K	Buy	+12,067	New	+$192K	﹤0.01%	2970
2024 Q4	–	Sell	-12,078	Closed	-$280K	–	2870
2024 Q3	$280K	Buy	12,078 +378	+3%	+$8.09K	﹤0.01%	2423
2024 Q2	$285K	Sell	11,700 -62,525	-84%	-$1.9M	﹤0.01%	2289
2024 Q1	$2.51M	Sell	74,225 -85,648	-54%	-$3.03M	﹤0.01%	1309
2023 Q4	$5.04M	Sell	159,873 -12,329	-7%	-$293K	0.01%	947
2023 Q3	$4.4M	Buy	172,202 +121,526	+240%	+$3.74M	0.01%	978
2023 Q2	$1.45M	Buy	+50,676	New	+$1.38M	﹤0.01%	1401
2021 Q1	–	Sell	-11,914	Closed	-$517K	–	2189
2020 Q4	$517K	Sell	11,914 -4,842	-29%	-$328K	﹤0.01%	1765
2020 Q3	$719K	Buy	+16,756	New	+$832K	﹤0.01%	1573

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's ARCT Position: Q1 2026 in Review

AQR Capital Management increased its Arcturus Therapeutics (ARCT) stake by 272% in Q1 2026, buying an estimated $860K and bringing the position to 161,278 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2646.

AQR Capital Management first reported a position in ARCT in Q3 2020 and has held it in 12 quarters since. The position peaked at $5.04M in Q4 2023. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

AQR Capital Management held 161,278 shares of Arcturus Therapeutics worth $1.25M as of Q1 2026.
AQR Capital Management bought 117,875 Arcturus Therapeutics shares in Q1 2026, an estimated $860K.
Arcturus Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2646 holding.
AQR Capital Management first reported a position in Arcturus Therapeutics in Q3 2020 and has held it in 12 quarters since.
AQR Capital Management's Arcturus Therapeutics position peaked at $5.04M in Q4 2023.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.